The global vaginitis therapeutics market size was estimated to be USD 3.52 billion in 2023 and is expected to reach at USD 8.74 billion by 2034 with a CAGR of 8.62% during the forecast period 2024-2034. Increasing prevalence of vaginitis, growing awareness regarding the importance of maintaining good vaginal health among women population, surge in demand for improved healthcare infrastructure, rising awareness initiatives by government & non-government organizations, increasing research & development activities by major market players, growing number of clinical trial procedures, surge in endeavors focused on the development of innovative formulations, and rising introduction of novel drugs for the treatment of vaginitis are some of the key factors boosting the market growth.
Rising introduction of novel drugs for the treatment of vaginitis is predicted to boost the market growth during the forecast period. Vaginitis is a prevalent medical condition in women, marked by previously undetected complications and morbidity. Extensive research in recent years has contributed to the development of treatment options for various forms of vaginitis. Women, especially during their reproductive years, are susceptible to vaginitis, which can be triggered by an imbalance in the vaginal microflora. Consequently, industry participants are emphasizing the creation of innovative medications for vaginitis. For instance, in July 2023, Daré Bioscience, Inc., a leader in women’s health innovation, reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% with collaborator Organon, and announced that Organon will pay Daré $1.0 million in July 2023.
By type, anti-bacterial was the highest revenue-grossing segment in the global vaginitis therapeutics market in 2023 owing to the increasing prevalence of bacterial vaginosis, rising approvals by regulatory bodies for improved treatment options, and growing launch of advanced treatment options. For instance, in June 2022, Duchesnay Inc, a Canadian pharmaceutical company with a focus on women's health, has introduced Vablys, which is the first prescription antiseptic and anti-infective treatment for bacterial vaginosis in women below the age of 55. This product features multiple modes of action and anti-infective properties effective against various pathogens. Additionally, hormonal treatment is predicted to grow at fastest CAGR during the forecast period owing to the presence of strong pipeline drugs, growing prevalence of vaginitis, increasing preference for oral hormonal treatments due to their convenience & efficacy.
By route of administration, oral was the highest revenue-grossing segment in the global vaginitis therapeutics market in 2023 owing to their convenience & ease of use, increasing clinical trial procedures, and growing introduction of new products. Additionally, vaginal is predicted to grow at fastest CAGR during the forecast period owing to the rising focus on development of innovative treatment options and surge in research & development activities. For instance, in May 2023, Gedea Biotech has initiated the treatment of the first patients with its flagship product, pHyph, which is a vaginal tablet designed for topical treatment. The objective of this open-label study is to validate the safety and effectiveness of pHyph in managing adult women with confirmed Vulvo Vaginal Candidiasis (VVC) and in reestablishing a healthy vaginal microbiome to prevent the recurrence of the infection. The study is being carried out at four gynecological clinics in Sweden.
By schedule, prescription was the highest revenue-grossing segment in the global vaginitis therapeutics market in 2023 owing to the enhanced effectiveness and safety of prescription medications for severe and recurrent vaginitis and surge in prescription of novel drugs by healthcare professionals. Additionally, over-the-counter (OTC) is predicted to grow at fastest CAGR during the forecast period owing to the availability of a diverse array of over-the-counter (OTC) drugs, including vaginal creams, gels, & more and increasing launch of new medications. For instance, in April 2022, Solosec (secnidazole) is an oral antibiotic intended for single-dose use. It is approved for the treatment of bacterial vaginosis in female patients aged 12 years and older, as well as for trichomoniasis in adults. Lupin Pharmaceuticals is responsible for the manufacturing and distribution of the drug, while Exeltis handles its marketing.
By distribution channel, mail order pharmacies was the highest revenue-grossing segment in the global vaginitis therapeutics market in 2023 owing to the increase in pharmaceutical sales through mail-order pharmacies and surge in demand of prescription drugs through mail & various internet outlets by patients. Additionally, hospital pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of vaginitis, surge in demand for innovative treatment options, and rising collaborations within market players. For instance, in February 2023, Basilea Pharmaceutica Ltd has revealed that the robust sales performance of the antifungal medication Cresemba (isavuconazole) by its licensing partner Pfizer Inc. in the Asia Pacific region and China has surpassed the set threshold, leading to a sales milestone payment of $1.25 million.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in well-established healthcare infrastructure, growing prevalence of disease, rising favorable government initiatives, increasing awareness regarding vaginal health among women, and surge in research & development activities. For instance, in September 2023, LABthera-001, which is in clinical development by AtoGen and is currently in Phase I for the treatment of Bacterial Vaginosis, is showing promise. According to data from GlobalData, Phase I drugs for Bacterial Vaginosis have a 100% Phase Transition Success Rate (PTSR) benchmark for advancing into Phase II, suggesting a positive outlook for LABthera-001 in its development. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing awareness about early disease diagnosis, rising focus on development of effective drugs, and growing introduction of new products. For instance, in May 2022, The Consumer Health division of Bayer has introduced an updated and enhanced line of Canesten, their anti-fungal treatment solution, in India.
Rising introduction of novel drugs for the treatment of vaginitis is predicted to boost the market growth during the forecast period. Vaginitis is a prevalent medical condition in women, marked by previously undetected complications and morbidity. Extensive research in recent years has contributed to the development of treatment options for various forms of vaginitis. Women, especially during their reproductive years, are susceptible to vaginitis, which can be triggered by an imbalance in the vaginal microflora. Consequently, industry participants are emphasizing the creation of innovative medications for vaginitis. For instance, in July 2023, Daré Bioscience, Inc., a leader in women’s health innovation, reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% with collaborator Organon, and announced that Organon will pay Daré $1.0 million in July 2023.
By type, anti-bacterial was the highest revenue-grossing segment in the global vaginitis therapeutics market in 2023 owing to the increasing prevalence of bacterial vaginosis, rising approvals by regulatory bodies for improved treatment options, and growing launch of advanced treatment options. For instance, in June 2022, Duchesnay Inc, a Canadian pharmaceutical company with a focus on women's health, has introduced Vablys, which is the first prescription antiseptic and anti-infective treatment for bacterial vaginosis in women below the age of 55. This product features multiple modes of action and anti-infective properties effective against various pathogens. Additionally, hormonal treatment is predicted to grow at fastest CAGR during the forecast period owing to the presence of strong pipeline drugs, growing prevalence of vaginitis, increasing preference for oral hormonal treatments due to their convenience & efficacy.
By route of administration, oral was the highest revenue-grossing segment in the global vaginitis therapeutics market in 2023 owing to their convenience & ease of use, increasing clinical trial procedures, and growing introduction of new products. Additionally, vaginal is predicted to grow at fastest CAGR during the forecast period owing to the rising focus on development of innovative treatment options and surge in research & development activities. For instance, in May 2023, Gedea Biotech has initiated the treatment of the first patients with its flagship product, pHyph, which is a vaginal tablet designed for topical treatment. The objective of this open-label study is to validate the safety and effectiveness of pHyph in managing adult women with confirmed Vulvo Vaginal Candidiasis (VVC) and in reestablishing a healthy vaginal microbiome to prevent the recurrence of the infection. The study is being carried out at four gynecological clinics in Sweden.
By schedule, prescription was the highest revenue-grossing segment in the global vaginitis therapeutics market in 2023 owing to the enhanced effectiveness and safety of prescription medications for severe and recurrent vaginitis and surge in prescription of novel drugs by healthcare professionals. Additionally, over-the-counter (OTC) is predicted to grow at fastest CAGR during the forecast period owing to the availability of a diverse array of over-the-counter (OTC) drugs, including vaginal creams, gels, & more and increasing launch of new medications. For instance, in April 2022, Solosec (secnidazole) is an oral antibiotic intended for single-dose use. It is approved for the treatment of bacterial vaginosis in female patients aged 12 years and older, as well as for trichomoniasis in adults. Lupin Pharmaceuticals is responsible for the manufacturing and distribution of the drug, while Exeltis handles its marketing.
By distribution channel, mail order pharmacies was the highest revenue-grossing segment in the global vaginitis therapeutics market in 2023 owing to the increase in pharmaceutical sales through mail-order pharmacies and surge in demand of prescription drugs through mail & various internet outlets by patients. Additionally, hospital pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of vaginitis, surge in demand for innovative treatment options, and rising collaborations within market players. For instance, in February 2023, Basilea Pharmaceutica Ltd has revealed that the robust sales performance of the antifungal medication Cresemba (isavuconazole) by its licensing partner Pfizer Inc. in the Asia Pacific region and China has surpassed the set threshold, leading to a sales milestone payment of $1.25 million.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in well-established healthcare infrastructure, growing prevalence of disease, rising favorable government initiatives, increasing awareness regarding vaginal health among women, and surge in research & development activities. For instance, in September 2023, LABthera-001, which is in clinical development by AtoGen and is currently in Phase I for the treatment of Bacterial Vaginosis, is showing promise. According to data from GlobalData, Phase I drugs for Bacterial Vaginosis have a 100% Phase Transition Success Rate (PTSR) benchmark for advancing into Phase II, suggesting a positive outlook for LABthera-001 in its development. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing awareness about early disease diagnosis, rising focus on development of effective drugs, and growing introduction of new products. For instance, in May 2022, The Consumer Health division of Bayer has introduced an updated and enhanced line of Canesten, their anti-fungal treatment solution, in India.
Segmentation: Vaginitis Therapeutics Market Report 2023 - 2034
Vaginitis Therapeutics Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Anti-bacterial
- Hormone
- Anti-fungal
Vaginitis Therapeutics Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Cutaneous
- Oral
- Vaginal
Vaginitis Therapeutics Market Analysis & Forecast by Schedule 2023 - 2034 (Revenue USD Bn)
- Prescription
- Over-the-counter (OTC)
Vaginitis Therapeutics Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Drug Stores
- Hospital Pharmacies
- Mail Order Pharmacies
- Retail Pharmacies
Vaginitis Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Vaginitis Therapeutics Market: Type Estimates & Trend Analysis
8. Vaginitis Therapeutics Market: Route of Administration Estimates & Trend Analysis
9. Vaginitis Therapeutics Market: Schedule Estimates & Trend Analysis
10. Vaginitis Therapeutics Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Vaginitis Therapeutics Market
13. Europe Global Vaginitis Therapeutics Market
14. Asia Pacific Global Vaginitis Therapeutics Market
15. Latin America Global Vaginitis Therapeutics Market
16. MEA Global Vaginitis Therapeutics Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Daré Bioscience Inc.
- Pfizer Inc.
- Merck & Co.
- Duchesnay Inc
- Novartis AG
- Bayer AG
- Gedea Biotech
- Lupin Pharmaceuticals Inc.
- Symbiomix Therapeutics Inc.
- Basilea Pharmaceutica Ltd
- Mission Pharmacal Company
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.52 Billion |
| Forecasted Market Value ( USD | $ 8.74 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
